ME 1071

Drug Profile

ME 1071

Alternative Names: CP 3242; ME-1071

Latest Information Update: 14 Oct 2011

Price : $50

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Meiji Seika Pharma
  • Class Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Gram-negative infections; Pseudomonal infections

Most Recent Events

  • 01 Apr 2011 Meiji Seika Kaisha is now called Meiji Seika Pharma
  • 28 Oct 2008 Antimicrobial data from in vitro studies presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,
  • 02 Oct 2007 Preclinical trials in Gram-negative infections in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top